CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Cost of sight

The ground-breaking genetic therapy Luxturna will cost $425,000 per eye


A new gene therapy for the treatment of the inherited retinal dystrophy will come with a $850,000 (£627241) price tag.

Luxturna, developed by Spark Therapeutics, became the first gene therapy for an inherited disorder to receive approval from the US Food and Drug Administration in December.

Spark Therapeutics has reached an agreement in principle with Harvard Pilgrim and Express Scripts to manufacture the one-time treatment at a cost of $425,000 (£313,624) per eye.

The condition that Luxturna targets is retinal dystrophy due to a mutation of the RPE65 gene.

The safety and efficacy of Luxturna were established in a clinical development programme with 41 patients between the ages of four and 44 years.

The primary evidence of efficacy of Luxturna was based on a phase three study with 31 participants by measuring the change from baseline to one year in a subject’s ability to navigate an obstacle course at various light levels.

The group of patients that received Luxturna demonstrated significant improvements in their ability to complete the obstacle course at low light levels in comparison to the control group.